SCHEMBL2929280

SCHEMBL2929280

CC(C)(C)NS(=O)(=O)c1ccc(F)cc1B(O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 2/20 0.39
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
ALOX5AP P20292 6/20 0.38
FEN1 P39748 6/20 0.38
NSD2 O96028 2/20 0.36
PARG Q86W56 1/20 0.36
CNR1 P21554 1/20 0.35
MEP1B Q16820 1/20 0.35
CCR2 P41597 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6166172 0.82 ALDH1A1 (0.44) ALDH1A1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL2937380 0.81 CA1 (0.39) ALDH1A1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL24429412 0.80 CCR2 (0.50) ALDH1A1CYP3A4CYP2C9MAPK1KMT2A
SCHEMBL27886350 0.78 L3MBTL1 (0.42) ALDH1A1CYP3A4CYP2C9KMT2AMAPT
SCHEMBL8023235 0.78 MCL1 (0.51) ALDH1A1CYP3A4CYP2C9MAPK1KMT2A
SCHEMBL16061931 0.78 WDR5 (0.41) MAPK1KMT2ASMN1; SMN2MEN1LMNA
SCHEMBL8035016 0.76 ALDH1A1 (0.44) ALDH1A1CYP3A4CYP2C9MAPK1KMT2A
SCHEMBL8023563 0.76 ALDH1A1 (0.44) ALDH1A1CYP3A4CYP2C9MAPK1KMT2A
SCHEMBL519774 0.76 NSD2 (0.47) ALDH1A1KMT2AMAPTSMN1; SMN2KDM4E
SCHEMBL24429345 0.76 ALDH1A1 (0.50) ALDH1A1CYP3A4CYP2C9MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021330-B1 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA NV (BE) 2010-09-22 EP disclosed
EP-2021330-A2 BENZIMIDAZOLE MODULATORS OF VR1 Janssen Pharmaceutica, N.V. (BE) 2009-02-11 EP disclosed
WO-2007130780-A2 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-15 WO disclosed
EP-1254136-A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD (KR) 2005-06-01 EP disclosed
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof LG CHEM INVESTMENT LTD. (KR) 2003-04-03 US disclosed
EP-1254136-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG Chem Investment, Ltd. (KR) 2002-11-06 EP disclosed
WO-2001055146-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD. (KR) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof F2, F12, TFPI ALDH1A1 1388/4885CYP3A4 114/4885CYP2C9 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.